BioLineRX
BLRX
21 hedge funds and large institutions have $17M invested in BioLineRX in 2015 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
5% more funds holding
Funds holding: 20 → 21 (+1)
42% less capital invested
Capital invested by funds: $29.3M → $17M (-$12.3M)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$711K |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$98.2K |
| 3 |
AL
Airain Ltd
St. Peter Port,
Guernsey
|
+$35.2K |
| 4 |
Jane Street
New York
|
+$32K |
| 5 |
Millennium Management
New York
|
+$30.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$217K |
| 2 |
O
OrbiMed
New York
|
-$172K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$154K |
| 4 |
NCCM
Nine Chapters Capital Management
Short Hills,
New Jersey
|
-$125K |
| 5 |
SM
Senvest Management
New York
|
-$120K |
BLRX Hedge Fund Activity: Q3 2015 in Review
21 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q3 2015, worth a combined $17M — down 42% from $29.3M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BLRX positions and 3 closed out — a net gain of 1 holder — while 4 added to existing stakes and 7 trimmed.
The largest buyer was Broadfin Capital, adding an estimated $711K. The largest seller was Deutsche Bank, cutting an estimated $217K.
- 21 institutional investors held BioLineRX (BLRX) as of Q3 2015, up from 20 in Q2 2015.
- Funds reported $17M of BioLineRX stock for Q3 2015, down 42% quarter-over-quarter.
- 4 funds opened new BioLineRX positions in Q3 2015 and 3 closed out, a net change of +1 holder.
- The largest BioLineRX buyer in Q3 2015 was Broadfin Capital, an estimated $711K added.
- The largest BioLineRX seller in Q3 2015 was Deutsche Bank, an estimated $217K sold.
Based on aggregated 13F filings for Q3 2015.